Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)

Size: px
Start display at page:

Download "Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)"

Transcription

1 Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)

2 Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy in all patient types including previously treated patients, cirrhotic and black patients Orally effective regimens, IFN free Shorter treatment durations Improved side-effect profiles

3 Selected Antivirals for the Treatment of Chronic Hepatitis C, 2012 New agents covered in this presentation, all in Phase 3 trials Compound Sponsor Activity Peginterferon Lambda-1a Sofosbuvir (GS-7977) Simeprevir (TMC435) Bristol-Myers Squibb Gilead Janssen Type III interferon immune modulator Uridine nucleotide analog NS5B polymerase inhibitor NS3/4A protease inhibitor

4 Emerging Therapies for HCV: Highlights from AASLD 2012 November 9-13, 2012 Boston, MA Peginterferon Lambda 1a (Lambda) Compared to Peginterferon Alfa 2a (Alfa) in Treatment Naïve Patients With HCV Genotypes (GT) 1 or 4: SVR24 Results From EMERGE Phase 2b Muir AJ, Hillson JL, Gray TE, Xu D, Ishak L, Freeman JA, Fontana D, Horga A, Lopez-Talavera JC Abstract 214, AASLD 2012

5 PegIFN Lambda-1a vs. PegIFN Alfa-2a in Treatment- Naïve Genotype 1 or 4 HCV Patients Objective: To investigate efficacy and tolerability of PegIFN lambda-1a (Lambda) compared to the efficacy and tolerability of PegIFN alfa-2a (Alfa) in treatment-naïve patients with HCV genotypes 1 or 4 Lambda is a pegylated type III interferon that exerts antiviral effects through a unique receptor with limited distribution outside the liver Muir AJ et al. Hepatology 2012; 56(Suppl S1):299A

6 PegIFN Lambda-1a vs. PegIFN Alfa-2a in Treatment- Naïve Genotype 1 or 4 HCV Patients Methods 407 non-cirrhotic, treatment-naïve patients infected with HCV GT1: N=384 GT4: N=23 Treatment: Lambda: 120, 180, or 240 μg weekly Alfa: 180 μg weekly All patients received daily ribavirin Treatment duration: 48 weeks Muir AJ et al. Hepatology 2012; 56(Suppl S1):299A

7 PegIFN Lambda-1a vs. PegIFN Alfa-2a in Treatment- Naïve Genotype 1 or 4 HCV Patients Efficacy HCV RNA <LLOQ (% patients) RVR (Week 4) cevr (Week 12 ETR (Week 48) SVR24 (Week 72) Lambda 120 ug + RBV (N=98) Lambda 180 ug + RBV (N=102) Lambda 240 ug + RBV (N=104) Alfa 180 ug + RBV (N=103) Muir AJ et al. Hepatology 2012; 56(Suppl S1):299A

8 PegIFN Lambda-1a vs. PegIFN Alfa-2a in Treatment- Naïve Genotype 1 or 4 HCV Patients HCV RNA concentration over time Lambda 120 g Lambda 180 g Lambda 240 g Alfa-2a 180 g Lambda is asociated with a faster decline in HCV RNA levels Muir AJ et al. Hepatology 2012; 56(Suppl S1):299A

9 PegIFN Lambda-1a vs. PegIFN Alfa-2a in Treatment- Naïve Genotype 1 or 4 HCV Patients Safety Results: Adverse Events Adverse Events n (%) Lambda 120 μg N=98 Lambda 180 μg N=102 Lambda 240 μg N=104 Alfa 180 μg N=103 Serious adverse events 6 (6.1) 3 (2.9) 9 (8.7) 7 (6.8) IFN dose reductions 6 (6.1) 8 (7.8) 76 (73.1) 29 (28.2) RBV dose held/reduced 11 (11.2) 11 (10.8) 12 (11.5) 34 (33.0) Flu-like symptoms (pyrexia, chills, or pain) Musculoskeletal (arthralgia, myalgia, or back pain) 17 (17.3) 13 (12.7) 8 (7.7) 47 (45.6) 21 (21.4) 16 (15.7) 22 (21.2) 48 (46.6) Muir AJ et al. Hepatology 2012; 56(Suppl S1):299A

10 PegIFN Lambda-1a vs. PegIFN Alfa-2a in Treatment- Naïve Genotype 1 or 4 HCV Patients Safety Results: Laboratory Values Laboratory Abnormalities n (%) Hemoglobin <10 g/dl or >3.4 g/dl below baseline Lambda 120 μg N=98 Lambda 180 μg N=102 Lambda 240 μg N=104 Alfa 180 μg N=103 27/97 (27.8) 23/101 (22.8) 19/102 (18.6) 64/103 (62.1) Neutrophils <1000/mm 3 1/97 (1.0) 2/101 (2.0) 1/102 (1.0) 44/103 (42.7) Platelets <100,000/mm 3 0 2/101 (2.0) 0 20/103 (19.4) ALT >5xULN 1/98 (1.0) 1/101 (1.0) 10/102 (9.8) 4/103 (3.9) Direct bilirubin >1.2 mg/dl 0 5/101 (5.0) 13/102 (12.7) 2/103 (1.9) Muir AJ et al. Hepatology 2012; 56(Suppl S1):299A

11 PegIFN Lambda-1a vs. PegIFN Alfa-2a in Treatment- Naïve Genotype 1 or 4 HCV Patients Conclusions Compared to Alfa, treatment with Lambda is associated with comparable efficacy in non-cirrhotic patients chronically infected with HCV GT1 or 4 Patients treated with Lambda experienced less hematologic toxicity and fewer musculoskeletal and flulike symptoms Improved safety profile supports further evaluation of Lambda in combination with direct-acting antiviral agents Muir AJ et al. Hepatology 2012; 56(Suppl S1):299A

12 Emerging Therapies for HCV: Highlights from AASLD 2012 November 9-13, 2012 Boston, MA Once Daily Sofosbuvir (GS-7977) plus PEG/RBV: High Early Response Rates Are Maintained During Post-Treatment Follow-Up In Treatment-Naïve Patients With HCV Genotype 1, 4, and 6 Infection in the ATOMIC Study Hassanein T, Lawitz E, Crespo I, Davis M, DeMicco MP, Nelson DR, Bernstein DE, Afdhal N, Jacobson IM, Vierling JM, Gordon SC, Anderson J, Hyland RH, Hindes R, Symonds WT, Albanis E, Arora S, Kowdley KV Abstract 230, AASLD 2012

13 ATOMIC Trial Update: Sofosbuvir (GS-7997) + PEG/RBV in Genotypes 1, 4, and 6 HCV Follow-up Objective To determine the optimal duration of treatment for the uridine nucleotide analog sofosbuvir (SOF, formerly GS- 7977) 400 mg once daily combined with pegylated interferon alfa-2a (PEG) and ribavirin (RBV) in treatment naïve patients chronically infected with HCV genotypes 1, 4, or 6 Hassanein T et al. Hepatology 2012; 56(Suppl S1):307A

14 ATOMIC Trial Update: Sofosbuvir (GS-7997) + PEG/RBV in Genotypes 1, 4, and 6 HCV Follow-up Study Design Day 1 Wk 12 Wk 24 Group A N=52 SOF + PEG + RBV GT1 Group B N=125 SOF + PEG + RBV GT1, 4, 6 Group C N=155 SOF + PEG + RBV SOF (n=75) SOF + RBV (n=75) GT1 Non-cirrhotic, treatment-naive patients with with genotype 1 were randomized 1:2:3 into open-label arms *Of the 125 patients enrolled in Arm B, 11 were genotype 4 and 5 were genotype 6 Hassanein T et al. Hepatology 2012; 56(Suppl S1):307A

15 ATOMIC Trial Update: Sofosbuvir (GS-7997) + PEG/RBV in Genotypes 1, 4, and 6 HCV Follow-up Efficacy overall % 94% 94% 90% 98% 99% 94% 92% 97% 99% 93% 91% Week 4 EOT Patients with HCV RNA <LOD (%) SVR4 SVR SOF+PEG+RBV 12 Wks SOF+PEG+RBV 24 Wks SOF+PEG+RBV Wks Hassanein T et al. Hepatology 2012; 56(Suppl S1):307A

16 ATOMIC Trial Update: Sofosbuvir (GS-7997) + PEG/RBV in Genotypes 1, 4, and 6 HCV Follow-up Efficacy in Genotype 4 and 6 Patients with HCV RNA <LOD (%) % 100% 100% 100% 100% 82% 82% 100% Week 4 EOT SVR4 SVR GT4 (n=11) SOF+PEG+RBV 24 Wks GT6 (n=5) SOF+PEG+RBV 24 Wks Hassanein T et al. Hepatology 2012; 56(Suppl S1):307A

17 ATOMIC Trial Update: Sofosbuvir (GS-7997) + PEG/RBV in Genotypes 1, 4, and 6 HCV Follow-up Adverse Events Sofosbuvir + PEG+RBV 12 wks (n=52) Sofosbuvir + PEG+RBV 24 wks (n=125) Sofosbuvir + PEG+RBV 12 wks + 12 wks (n=155) Serious AEs, n (%) 2 (4) 6 (5) 4 (3) AEs leading to d/c of any drug, n (%) 3 (6) 20 (16) 7 (5) Hassanein T et al. Hepatology 2012; 56(Suppl S1):307A

18 ATOMIC Trial Update: Sofosbuvir (GS-7997) + PEG/RBV in Genotypes 1, 4, and 6 HCV Follow-up Adverse Events Most common AEs (>15%, overall) n (%) Sofosbuvir + PEG+RBV 12 wks (n=52) Sofosbuvir + PEG+RBV 24 wks (n=125) Sofosbuvir + PEG+RBV 12 wks + 12 wks (n=155) Fatigue 25 (48) 63 (50) 86 (55) Headache 14 (27) 38 (30) 65 (42) Nausea 16 (31) 43 (34) 51 (33) Insomnia 12 (23) 28 (22) 36 (23) Anemia 7 (13) 31 (25) 34 (22) Rash 7 (13) 26 (21) 39 (25) Chills 15 (29) 25 (20) 29 (19) Neutropenia 12 (23) 25 (20) 22 (14) Pyrexia 18 (35) 15 (12) 26 (17) Decreased Appetite 7 (13) 17(14) 34 (22) Diarrhea 11 (21) 23 (18) 20 (13) Arthralgia 15 (29) 23 (18) 14 (9) Hassanein T et al. Hepatology 2012; 56(Suppl S1):307A

19 ATOMIC Trial Update: Sofosbuvir (GS-7997) + PEG/RBV in Genotypes 1, 4, and 6 HCV Follow-up Grade 3 Hematology and Chemistry Laboratory Abnormalities in >1% of Patients Hassanein T et al. Hepatology 2012; 56(Suppl S1):307A Sofosbuvir + PEG+RBV 12 wks (n=52) Sofosbuvir + PEG+RBV 24 wks (n=125) Sofosbuvir + PEG+RBV 12 wks + 12 wks (n=155) Hemoglobin decreased 3 (6) 8 (6) 11 (8) WBCs decreased 6 (11) 9 (7) 4 (3) Lymphocytes decreased 3 (6) 14 (11) 3 (2) Neutrophils decreased 13 (25) 27 (22) 27 (17) Platelets decreased 2 (4) 1 (<1) 1 (<1) AST 2 (4) 4 (3) 2 (1) ALT 2 (4) 0 2 (1) Hyperglycemia 0 2 (2) 5 (3) Lipase 2 (4) 2 (2) 1 (<1)

20 ATOMIC Trial Update: Sofosbuvir (GS-7997) + PEG/RBV in Genotypes 1, 4, and 6 HCV Follow-up Conclusions Sofosbuvir 400 mg once daily + PEG/RBV for 12 weeks appears to be safe and highly effective for the treatment of patients with HCV genotype 1 12 weeks of sofosbuvir + PEG/RBV was as effective as 24 weeks of therapy in patients with HCV genotype 1 24 weeks of sofosbuvir 400 mg once daily + PEG/RBV appears to be highly effective in HCV genotype 4 and 6 Hassanein T et al. Hepatology 2012; 56(Suppl S1):307A

21 Emerging Therapies for HCV: Highlights from AASLD 2012 November 9-13, 2012 Boston, MA Efficacy and Tolerability of TMC mg Once Daily with Peginterferonα-2a and Ribavirin for Treatment of HCV Genotype 1 Infection in Patients with Metavir Score F3 and F4 (Pillar and Aspire Trials) Poordad F, Fried MW, Zeuzem S, Ferenci P, Lenz O, Sinha R, Callewaert K, Peeters M, Beumont M Abstract 83, AASLD 2012

22 PILLAR and ASPIRE Trials: Efficacy and Safety of Simeprevir/PegIFN/RBV in HCV Patients with Advanced Liver Disease Objective To assess efficacy and safety of treatment with simeprevir (TMC435)/PegIFN/RBV vs. placebo/pegifn/rbv in F3/F4 treatment-naïve and treatment-experienced HCV patients Simeprevir is a NS3/4 protease inhibitor Poordad F et al. Hepatology 2012; 56(Suppl S1):233A

23 PILLAR and ASPIRE Trials: Efficacy and Safety of Simeprevir/PegIFN/RBV in HCV Patients with Advanced Liver Disease Methods Post hoc analysis performed to evaluate efficacy and safety/tolerability in F3/F4 patients in PILLAR and ASPIRE trials Simeprevir 150 mg dose groups only Simeprevir treatment duration groups pooled Poordad F et al. Hepatology 2012; 56(Suppl S1):233A

24 PILLAR and ASPIRE Trials: Efficacy and Safety of Simeprevir/PegIFN/RBV in HCV Patients with Advanced Liver Disease Study Design PILLAR: Treatment-naïve patients (including F3) SMV + PR Pbo + PR PR Post-therapy FU SMV + PR PR Post-therapy FU Pbo + PR PR Post-therapy FU RGT in SMV arms ASPIRE: Treatment-experienced patients (prior relapsers, partial and null responders including F3 and F4) SMV + PR Pbo + PR Post-therapy FU SMV + PR Pbo + PR Post-therapy FU SMV + PR Pbo + PR Poordad F et al. Hepatology 2012; 56(Suppl S1):233A Post-therapy FU Post-therapy FU 75 mg, n= mg, n=77 75 mg, n= mg, n=79 Control, n= mg, n= mg, n= mg, n= mg, n= mg, n= mg, n=65 Control, n= Weeks

25 PILLAR and ASPIRE Trials: Efficacy and Safety of Simeprevir/PegIFN/RBV in HCV Patients with Advanced Liver Disease Efficacy % 79% Placebo/ PR Simeprevir 150 mg/pr SVR24 (%) % 62% /7 15/19 PILLAR treatmentnaïve: F3 4% 1/23 ASPIRE treatmentexperienced: F3/F4 pooled 0 38/68 0/10 24/39 ASPIRE treatmentexperienced: F4 only Poordad F et al. Hepatology 2012; 56(Suppl S1):233A

26 PILLAR and ASPIRE Trials: Efficacy and Safety of Simeprevir/PegIFN/RBV in HCV Patients with Advanced Liver Disease Efficacy: Response-guided therapy* in treatment naïve F3 patients 84% (16/19) met RGT* criteria and ended treatment at week Simeprevir 150 mg/pr 94% SVR24 (%) *Response-guided therapy (RGT) criteria in simeprevir arms: End treatment at wk 24 if HCV RNA <25 IU/mL at wk 4 and undetectable at wks 12, 16 and 20; all other patients continued PR up to wk /16 PILLAR patients who met RGT Poordad F et al. Hepatology 2012; 56(Suppl S1):233A

27 PILLAR and ASPIRE Trials: Efficacy and Safety of Simeprevir/PegIFN/RBV in HCV Patients with Advanced Liver Disease Efficacy: Treatment-experienced SVR 24 by prior response to PegIFN/RBV in F3/F4 patients 100 SVR24 (%) % 67% 33% % 0/10 17/26 1/10 14/21 0/3 17/21 Relapser Partial Responder Null Responder 31% (4/13) null responders with cirrhosis (F4) achieved SVR24 Poordad F et al. Hepatology 2012; 56(Suppl S1):233A

28 PILLAR and ASPIRE Trials: Efficacy and Safety of Simeprevir/PegIFN/RBV in HCV Patients with Advanced Liver Disease Adverse events: Treatment-naïve and -experienced (pooled data) Proportion of patients with AEs over entire treatment phase, % F3/F4 patients Pbo PR (n=30) SMV 150 mg PR (n=87) F0-F2 patients Pbo PR (n=113) SMV 150 mg PR (n=267) Any AE Grade 3/4 AEs Serious AEs SMV/pbo discontinuation due to AE Death due to AE *AEs listed do not include changes in laboratory parameters Poordad F et al. Hepatology 2012; 56(Suppl S1):233A

29 PILLAR and ASPIRE Trials: Efficacy and Safety of Simeprevir/PegIFN/RBV in HCV Patients with Advanced Liver Disease Adverse events:* Treatment-naïve and -experienced (pooled data) Most common AEs (<25% in F3/F4 SMV patients) *AEs listed do not include changes in laboratory parameters Poordad F et al. Hepatology 2012; 56(Suppl S1):233A F3/F4 patients Pbo PR (n=30) SMV 150 mg PR (n=87) F0-F2 patients Pbo PR (n=113) SMV 150 mg PR (n=267) Fatigue Influenza-like illness Asthenia Pruritus Dry Skin Rash

30 PILLAR and ASPIRE Trials: Efficacy and Safety of Simeprevir/PegIFN/RBV in HCV Patients with Advanced Liver Disease Laboratory toxicities: Treatment-naïve and -experienced (pooled data) Proportion of patients with toxicities over entire treatment phase, % Hemoglobin At least Grade 2 (<9.5 g/dl) Grade 3 ( g/dl) Grade 4 (<6.5 g/dl) Absolute neutrophil count Grade 3 ( /mm 3 ) Grade 4 (<500/mm 3 ) Platelets Grade 3 (20,000-9,000/mm 2 ) Grade 4 (<20,000/mm 2 ) F3/F4 patients Pbo PR (n=30) SMV 150 mg PR (n=87) F0-F2 patients Pbo PR (n=113) SMV 150 mg PR (n=267) Poordad F et al. Hepatology 2012; 56(Suppl S1):233A

31 PILLAR and ASPIRE Trials: Efficacy and Safety of Simeprevir/PegIFN/RBV in HCV Patients with Advanced Liver Disease Laboratory toxicities: Treatment-naïve and -experienced (pooled data; cont) Proportion of patients with toxicities over entire treatment phase, % F3/F4 patients Pbo PR (n=30) SMV 150 mg PR (n=87) F0-F2 patients Pbo PR (n=113) SMV 150 mg PR (n=267) Creatinine Grade 3 or 4 (>3.0 x ULN) Total bilirubin Grade 3 (> x ULN) Grade 4 >5.0 x ULN) Majority of laboratory abnormalities were mild/moderate Poordad F et al. Hepatology 2012; 56(Suppl S1):233A

32 PILLAR and ASPIRE Trials: Efficacy and Safety of Simeprevir/PegIFN/RBV in HCV Patients with Advanced Liver Disease Conclusions Excellent SVR24 rates were obtained with simeprevir 150 mg combined with PegIFN/RBV in HCV genotype 1-infected, treatment naïve and - experienced patients Majority of treatment-naive patients were eligible for 24 week treatment duration and achieved >90% SVR24 F3/F4 null responders achieved 33% SVR24 Simeprevir/PegIFN/RBV has a favorable overall safety and tolerability profile Poordad F et al. Hepatology 2012; 56(Suppl S1):233A

33 Emerging Therapies for HCV: Highlights from AASLD 2012 November 9-13, 2012 Boston, MA Safety and Tolerability of TMC435 in Combination with Peginterferon α-2a and Ribavirin for Treatment of HCV Genotype 1 Infection in Treatment-Naïve and -Experienced patients (PILLAR and ASPIRE Trials) Fried MW, Poordad F, Zeuzem S, Ferenci P, Lenz O, Ouwerkerk-Mahadevan S, Peeters M, Sinha R, Beumont M Abstract 769, AASLD 2012

34 PILLAR and ASPIRE Trials: Safety and Tolerability of Simeprevir/PegIFN/RBV for Treatment-Naive and -Experienced HCV 1 Patients Objective To assess safety and tolerability of simeprevir 150 mg in combination with PegIFNα-2a and RBV for the treatment of HCV genotype 1 in treatment-naïve and treatmentexperienced patients (PILLAR and ASPIRE trials) Simeprevir (TCM435) is an NS3/4A HCV protease inhibitor Fried MW et al. Hepatology 2012; 56(Suppl S1):563A.

35 PILLAR and ASPIRE Trials: Safety and Tolerability of Simeprevir/PegIFN/RBV for Treatment-Naive and -Experienced HCV 1 Patients Methods Patients received simeprevir 75, 100 or 150 mg QD for 12, 24 or 48 weeks in combination with PegIFN/RBV for 24 or 48 weeks, or placebo/pegifn/rbv for 48 weeks (control) In PILLAR, response-guided therapy criteria were used to determine total treatment duration in simeprevir arms; treatment ended at week 24 if HCV RNA <25 IU/mL detectable/ undetectable at week 4 and <25 IU/mL undetectable at weeks 12, 16, and 20; all other patients continued PegIFN/RBV up to 48. Safety was evaluated with a pooled analysis of patients receiving simeprevir 150 mg QD (n=355) compared to control groups (n=143) Fried MW et al. Hepatology 2012; 56(Suppl S1):563A.

36 PILLAR and ASPIRE Trials: Safety and Tolerability of Simeprevir/PegIFN/RBV for Treatment-Naive and-experienced HCV 1 Patients Study Design PILLAR: Treatment-naïve patients (including F3) SMV + PR Pbo + PR PR Post-therapy FU SMV + PR PR Post-therapy FU Pbo + PR PR Post-therapy FU RGT in SMV arms ASPIRE: Treatment-experienced patients (prior relapsers, partial and null responders including F3 and F4) SMV + PR Pbo + PR Post-therapy FU SMV + PR Pbo + PR Post-therapy FU SMV + PR Pbo + PR Post-therapy FU Post-therapy FU 75 mg, n= mg, n=77 75 mg, n= mg, n=79 Control, n= mg, n= mg, n= mg, n= mg, n= mg, n= mg, n=65 Control, n= Weeks Fried MW et al. Hepatology 2012; 56(Suppl S1):563A.

37 PILLAR and ASPIRE Trials: Safety and Tolerability of Simeprevir/PegIFN/RBV for Treatment-Naive and -Experienced HCV 1 Patients Occurrence of AEs* Proportion of patients, % PILLAR and ASPIRE combined: First 12 weeks Pbo PR (n=143) SMV 150 mg PR (n=355) PILLAR and ASPIRE combined: Overall treatment duration Pbo PR (n=1433) SMV 150 mg PR (n=355) Grade 3/4 AEs Serious AEs AEs leading to SMV/placebo discontinuation AEs leading to discontinuation of any study drug *AEs listed do not include changes in laboratory parameters Fried MW et al. Hepatology 2012; 56(Suppl S1):563A.

38 PILLAR and ASPIRE Trials: Safety and Tolerability of Simeprevir/PegIFN/RBV for Treatment-Naive and -Experienced HCV 1 Patients Occurrence of AEs* (cont) AEs most frequently reported (>25% patients in pooled overall SMV 150 mg group ), % PILLAR and ASPIRE combined: First 12 weeks Pbo PR (n=143) SMV 150 mg PR (n=355) PILLAR and ASPIRE combined: Overall treatment duration Pbo PR (n=1433) SMV 150 mg PR (n=355) Fatigue Influenza-like illness Pruritus (all types) ǂ Headache Nausea *AEs listed do not include changes in laboratory parameters Treatment arms with different durations combined ǂ All types of rash or pruritus combined Fried MW et al. Hepatology 2012; 56(Suppl S1):563A.

39 PILLAR and ASPIRE Trials: Safety and Tolerability of Simeprevir/PegIFN/RBV for Treatment-Naive and -Experienced HCV 1 Patients Occurrence of AEs* (cont) AEs of clinical interest (regardless of causality), % PILLAR and ASPIRE combined: First 12 weeks Pbo PR (n=143) SMV 150 mg PR (n=355) PILLAR and ASPIRE combined: Overall treatment duration Pbo PR (n=1433) SMV 150 mg PR (n=355) Rash (all types) ǂ Rash (all types) ǂ, Grade Rash (all types) ǂ, Grade Anemia, at least Grade Neutropenia TBC TBC *AEs listed do not include changes in laboratory parameters These AEs are documented with other agents in the protease inhibitor class ǂ All types of rash or pruritus combined Fried MW et al. Hepatology 2012; 56(Suppl S1):563A.

40 PILLAR and ASPIRE Trials: Safety and Tolerability of Simeprevir/PegIFN/RBV for Treatment-Naive and -Experienced HCV 1 Patients Change in hemoglobin over study period* Mean SE of Actual Values of Hgb (g/dl) *Simeprevir 150 mg/pr or Placebo/PR in PILLAR and ASPIRE Fried MW et al. Hepatology 2012; 56(Suppl S1):563A.

41 PILLAR and ASPIRE Trials: Safety and Tolerability of Simeprevir/PegIFN/RBV for Treatment-Naive and -Experienced HCV 1 Patients Change in neutrophils over study period* Mean SE of Actual Values of Neutrophils (giga/l) *Simeprevir 150 mg/pr or Placebo/PR in PILLAR and ASPIRE Fried MW et al. Hepatology 2012; 56(Suppl S1):563A.

42 PILLAR and ASPIRE Trials: Safety and Tolerability of Simeprevir/PegIFN/RBV for Treatment-Naive and -Experienced HCV 1 Patients Change in platelets over study period* Mean SE of Actual Values of Platelets (giga/l) *Simeprevir 150 mg/pr or Placebo/PR in PILLAR and ASPIRE Fried MW et al. Hepatology 2012; 56(Suppl S1):563A.

43 PILLAR and ASPIRE Trials: Safety and Tolerability of Simeprevir/PegIFN/RBV for Treatment-Naive and -Experienced HCV 1 Patients Change in total bilirubin over study period* Mean SE of Actual Values of Total Bilirubin (mg/dl) *Simeprevir 150 mg/pr or Placebo/PR in PILLAR and ASPIRE Fried MW et al. Hepatology 2012; 56(Suppl S1):563A.

44 PILLAR and ASPIRE Trials: Safety and Tolerability of Simeprevir/PegIFN/RBV for Treatment-Naive and -Experienced HCV 1 Patients Conclusions Simeprevir 150 mg with PegIFN/RBV was generally well tolerated by both treatment-naïve and treatment-experienced patients in the PILLAR and ASPIRE trials Incidence of AEs, including serious AEs, was comparable between simeprevir-treated patients and PegIFN/RBV control groups There was no difference in mean change over time in hemoglobin, platelets or neutrophils during treatment, between simeprevir and control patients Transporter-mediated bilirubin elevations observed with simeprevir were mild, transient, and reversible Fried MW et al. Hepatology 2012; 56(Suppl S1):563A.

45 PegIFN and RBV remain vital components of HCV therapy Summary Improved safety profile supports further evaluation of PegIFN Lambda in combination with direct-acting antiviral agents for the treatment of chronic hepatitis C Sofosbuvir 400 mg once daily + PEG/RBV for 12 weeks appears to be safe and highly effective for the treatment of patients with HCV genotype 1; 24 weeks of sofosbuvir 400 mg once daily + PEG/RBV appears to be highly effective in HCV genotype 4 and 6

46 PegIFN and RBV remain vital components of HCV therapy Summary (cont) Excellent SVR24 rates were obtained with simeprevir 150 mg combined with PegIFN/RBV in HCV genotype 1- infected, treatment naïve and -experienced patients; majority of treatment-naive patients were eligible for 24 week treatment duration and achieved >90% SVR24 PegIFN and RBV when combined with DAA agents will continue to be important components of the HCV treatment armamentarium To treat now or to wait optimal decision-making requires knowledge of current developments

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and

More information

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1)

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Robert S. Brown, Jr., MD, MPH Frank Cardile Professor of Medicine Chief,

More information

Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.

Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours. Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship

More information

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1)

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Goals for Hepatitis C Therapy Compared to PegIFN/RBV, new products should offer: Improved efficacy Efficacy in all patient types including

More information

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor

More information

Bristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013

Bristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013 Bristol-Myers Squibb HCV Full Development Portfolio Overview Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013 1 BMS Agents in Clinical Development: DAAs and INF Lambda Lambda

More information

Evolution of Therapy in HCV

Evolution of Therapy in HCV Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR

More information

Hepatitis C Emerging Therapy Update: Reports From the Liver Meeting 2012

Hepatitis C Emerging Therapy Update: Reports From the Liver Meeting 2012 Reports From the Liver Meeting 212 Project ID: 521 Target Audience This activity has been designed to meet the educational needs of gastroenterologists, hepatologists, physician assistants, and nurse practitioners

More information

Hepatitis C Treatment 2014

Hepatitis C Treatment 2014 Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype

More information

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients 5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,

More information

Introduction. The ELECTRON Trial

Introduction. The ELECTRON Trial 63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver

More information

IFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster

IFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment

More information

CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA

CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and

More information

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center

More information

Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov

Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients

More information

Latest Treatment Updates for GT 2 and GT 3 Patients

Latest Treatment Updates for GT 2 and GT 3 Patients Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of

More information

Treatments of Genotype 2, 3,and 4: Now and in the future

Treatments of Genotype 2, 3,and 4: Now and in the future Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve

More information

Highlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases

Highlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with

More information

HCV Case Study. Treat Now or Wait for New Therapies

HCV Case Study. Treat Now or Wait for New Therapies HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented

More information

SYNOPSIS Final Clinical Study Report for Study AI444031

SYNOPSIS Final Clinical Study Report for Study AI444031 Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study

More information

Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial

Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1

More information

Update in the Management of Hepatitis C: What Does the Future Hold

Update in the Management of Hepatitis C: What Does the Future Hold Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana

More information

47 th Annual Meeting AISF

47 th Annual Meeting AISF 47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,

More information

Clinical Management: Treatment of HCV Mono-infection

Clinical Management: Treatment of HCV Mono-infection Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry

More information

Associate Professor of Medicine University of Chicago

Associate Professor of Medicine University of Chicago Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death

More information

SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano

SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed

More information

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on

More information

Update on the Treatment of HCV

Update on the Treatment of HCV Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure

More information

Background: Narlaprevir (SCH )

Background: Narlaprevir (SCH ) Once Daily Narlaprevir (SCH 9518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study Vierling J,

More information

Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.

Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours. Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship

More information

4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives

4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives 4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215

More information

Pivotal New England Journal of Medicine papers 2014 Phase 3 Trial data

Pivotal New England Journal of Medicine papers 2014 Phase 3 Trial data 4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:

More information

New Therapeutic Strategies: Polymerase Inhibitors

New Therapeutic Strategies: Polymerase Inhibitors New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2

More information

Antiviral agents in HCV

Antiviral agents in HCV Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million

More information

Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1

Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,

More information

How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy

How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum

More information

SVR Updates from the 2013 EASL

SVR Updates from the 2013 EASL Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations

More information

Treatment with the New Direct Acting Antivirals for Hepatitis C

Treatment with the New Direct Acting Antivirals for Hepatitis C Treatment with the New Direct Acting Antivirals for Hepatitis C Mary Olson, DNP, ANP-BC Clinical Trials Program Director Weill Cornell Medical College The Center for the Study of Hepatitis C Objectives

More information

VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES

VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade

More information

The HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)

The HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1) Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell

More information

Strategies towards cure of HCV infection: a personalized approach. Heiner Wedemeyer Hannover Medical School Hannover, Germany

Strategies towards cure of HCV infection: a personalized approach. Heiner Wedemeyer Hannover Medical School Hannover, Germany Strategies towards cure of HCV infection: a personalized approach Heiner Wedemeyer Hannover Medical School Hannover, Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Biolex,

More information

Treatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona

Treatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir

More information

New developments in HCV research and their implications for front-line practice

New developments in HCV research and their implications for front-line practice New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013

More information

Special Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting

Special Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual

More information

Interferon-based and interferon-free new treatment options

Interferon-based and interferon-free new treatment options Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt

More information

Oral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside

Oral combination therapy: future hepatitis C virus treatment? Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following

More information

November 2013 AASLD Investor Event 4 November

November 2013 AASLD Investor Event 4 November November 2013 AASLD Investor Event 4 November Maris Hartmanis, President and CEO Charlotte Edenius, EVP Development Bertil Samuelsson, CSA Rein Piir, EVP Corporate Affairs & IR Corporate presentation,

More information

HCV Treatment of Genotype 1: Now and in the Future

HCV Treatment of Genotype 1: Now and in the Future HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program

More information

HIV and Hepatitis C: Advances in Treatment

HIV and Hepatitis C: Advances in Treatment NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,

More information

Antiviral treatment in HCV cirrhotic patients on waiting list

Antiviral treatment in HCV cirrhotic patients on waiting list Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory

More information

TREATMENT OF GENOTYPE 2

TREATMENT OF GENOTYPE 2 Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,

More information

Ledipasvir-Sofosbuvir (Harvoni)

Ledipasvir-Sofosbuvir (Harvoni) HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical

More information

Protease inhibitor based triple therapy in treatment experienced patients

Protease inhibitor based triple therapy in treatment experienced patients Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber

More information

Treating HCV Genotype 2 & 3

Treating HCV Genotype 2 & 3 Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy

More information

EASL and The Future of HCV Treatment

EASL and The Future of HCV Treatment EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio

More information

6/2/2015. Interactive Case-Based Presentations and Audience Discussion

6/2/2015. Interactive Case-Based Presentations and Audience Discussion 6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi

More information

Direct Acting Antivirals for the Treatment of Hepatitis C Infection

Direct Acting Antivirals for the Treatment of Hepatitis C Infection Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment

More information

A treatment revolution: current management for chronic HCV

A treatment revolution: current management for chronic HCV A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research

More information

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate

More information

UPDATES IN HEPATITIS C

UPDATES IN HEPATITIS C UPDATES IN HEPATITIS C S A R A H N A I D O O, P H A R M, B C P S AP RI L 13, 2014 OBJECTIVES Be able to discuss changes in hepatitis c treatment Be able to provide recommendations to providers regarding

More information

Clinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.

Clinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago

More information

Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C

Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C Liver International ISSN 1478-3223 REVIEW ARTICLE Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C Nicole M. Welch and Donald M. Jensen University

More information

2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients

2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients 2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director

More information

Abstract 233. Post-treatment follow up. Pawlotsky JM, et al. 63rd AASLD; Boston, MA; November 9-13, 2012:. Abst ALV loading* RVR at W4

Abstract 233. Post-treatment follow up. Pawlotsky JM, et al. 63rd AASLD; Boston, MA; November 9-13, 2012:. Abst ALV loading* RVR at W4 Jean-Michel Pawlotsky, Shiv K. Sarin, Graham R. Foster, Cheng-Yuan Peng, Jens Rasenack, Robert Flisiak, Teerha Piratvisuth, Heiner Wedemeyer, Wan-Long Chuang, Wei Zhang and Nikolai V. Naoumov Abstract

More information

Updates in the Management of HCV: What Clinicians Who Care for Patients With HCV Need to Know Today

Updates in the Management of HCV: What Clinicians Who Care for Patients With HCV Need to Know Today Updates in the Management of HCV: What Clinicians Who Care for Patients With HCV Need to Know Today The treatment paradigm for hepatitis C virus (HCV) is changing very rapidly. In the short time since

More information

Why make this statement?

Why make this statement? HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed

More information

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data

More information

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were

More information

Gane et al. BMC Infectious Diseases (2017) 17:389 DOI /s

Gane et al. BMC Infectious Diseases (2017) 17:389 DOI /s Gane et al. BMC Infectious Diseases (2017) 17:389 DOI 10.1186/s12879-017-2444-3 RESEARCH ARTICLE Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced

More information

Updates on Current Status of HCV Therapy

Updates on Current Status of HCV Therapy Updates on Current Status of HCV Therapy K. Rajender Reddy, MD Professor of Medicine, Professor of Medicine in Surgery, Director of Hepatology and Medical Director of Liver Transplantation University of

More information

Parent drug: hours. Not reported Parent drug: 0.4 hours Major metabolite (GS ): 27 hours. ~61% to 65% bound to human plasma proteins

Parent drug: hours. Not reported Parent drug: 0.4 hours Major metabolite (GS ): 27 hours. ~61% to 65% bound to human plasma proteins Brand Name: Sovaldi Generic Name: sofosbuvir Manufacturer 3 : Gilead Sciences Inc. Drug Class 1,2 : Antiinfective, Antihepaciviral, Anti-HCV, NS5B polymerase inhibitor Uses: Labeled 1,2,3,4,5 : Chronic

More information

Treatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble

Treatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989

More information

2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only)

2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only) 2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-267, ribavirin, pegylated interferon Name of Active Ingredient: ABT-450, Ritonavir, ABT-267, Ribavirin, Pegylated interferon Individual

More information

Rome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING

Rome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN

More information

V.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain, R. Bailey, A. Neumann, P. Cronin, J. McHutchison, E. Pulkstenis, M.

V.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain, R. Bailey, A. Neumann, P. Cronin, J. McHutchison, E. Pulkstenis, M. COMPARABLE ANTIVIRAL RESPONSE RATES WITH ALBINTERFERON ALFA-2B DOSED AT Q2W OR Q4W INTERVALS IN NAIVE SUBJECTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C V.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain,

More information

ABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1

ABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1 ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical

More information

Michael Fried, MD University of North Carolina Chapel Hill, NC. Ira Jacobson, MD Weill Cornell Medical College New York, NY

Michael Fried, MD University of North Carolina Chapel Hill, NC. Ira Jacobson, MD Weill Cornell Medical College New York, NY Nezam Afdhal, MD Beth Israel Deaconess Medical Center Boston, MA Kim Brown, MD Henry Ford Hospital Detroit, MI Michael Fried, MD University of North Carolina Chapel Hill, NC Jordan Feld, MD Toronto Western

More information

CASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be?

CASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? CASE STUDY Pham Thi Thu Thuy MD, PhD Ho Chi Minh City Vietnam Serious Adverse

More information

Case 2: A 71-year-old man with cirrhosis

Case 2: A 71-year-old man with cirrhosis Case 2: A 71-year-old man with cirrhosis 1 JM, 71 year old African American male with known cirrhosis Asymptomatic apart from fatigue No prior history of decompensation Past history: Diabetes for 11 years

More information

Patients with Cirrhosis: Managing the HCV Peri-Transplant Patient

Patients with Cirrhosis: Managing the HCV Peri-Transplant Patient Patients with Cirrhosis: Managing the HCV Peri-Transplant Patient Fred Poordad, MD Professor of Medicine University of Texas Health Science Center VP, Academic and Clinical Affairs The Texas Liver Institute

More information

Feeling right at home

Feeling right at home Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements

More information

Experience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona

Experience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir

More information

Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos

Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology

More information

Genotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty

Genotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn

More information

Hepatitis C Virus Treatments: Present and Future

Hepatitis C Virus Treatments: Present and Future Hepatitis C Virus Treatments: Present and Future Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Boehringer Ingelheim,

More information

Update on chronic hepatitis C treatment: current trends, new challenges, what next?

Update on chronic hepatitis C treatment: current trends, new challenges, what next? Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15

More information

9/21/2014. Sarah Naidoo, PharmD, BCPS September 26, 2014

9/21/2014. Sarah Naidoo, PharmD, BCPS September 26, 2014 Sarah Naidoo, PharmD, BCPS September 26, 2014 Be able to discuss changes in hepatitis C treatment Be able to provide recommendations to providers regarding hepatitis C treatment Be able to provide patient

More information

How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France

How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding

More information

Future strategies with new DAAs

Future strategies with new DAAs Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks

More information

Dr. Siddharth Srivastava

Dr. Siddharth Srivastava Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.

More information

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014

More information

Treatment of HCV in 2016

Treatment of HCV in 2016 5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,

More information

The nonstructural (NS)5B polymerase inhibitor,

The nonstructural (NS)5B polymerase inhibitor, RAPID COMMUNICATION Ledipasvir-Sofosbuvir Plus Ribavirin for Patients With Genotype 1 Hepatitis C Virus Previously Treated in Clinical Trials of Sofosbuvir Regimens David Wyles, 1 Paul Pockros, 2 Giuseppe

More information

HEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA

HEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA NEW TREATMENTS FOR HEPATITIS C Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research

More information

Stick or twist management options in hepatitis C

Stick or twist management options in hepatitis C Stick or twist management options in hepatitis C Dr. Chris Durojaiye & Dr. Matthijs Backx SpR Microbiology and Infectious Diseases University Hospital of Wales, Cardiff Patient history 63 year old female

More information

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International

More information

The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago

The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years Nancy Reau, MD Associate Professor University of Chicago Learning Objectives Upon completion of this presentation, learners should

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred

More information